A Phase 3 interventional study of BCD-085 and placebo in Ankylosing Spondylitis, sponsored by Biocad. Completed at 7 sites in Russia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Biocad · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
BCD-085-5 is an International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-5 trial patients with active ankylosing spondylitis will receive 120 mg of BCD-085 subcutaneously every other week or placebo up to Week 16. Starting from week 16 all patients will receive BCD-085. Efficacy, PK and safety parameters will be evaluated.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.
This study's enrollment of 228 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Browse Spondylitis, Ankylosing studies →Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BCD-085
Other: placebo
120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
Also known as: netakimab
2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
ASAS40 rate at Week 16
Percentage of patients with ASAS40 response after 16 weeks of therapy (percentage of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 40%)
Time frame: Week 16
ASAS20 rate
Percentage of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 20%
Time frame: Week 4, 8, 12, 16, 24, 36, 52
Change from baseline in BASDAI
Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score in comparison with screening (from 0 to 10). The maximum change is considered to be better outcome
Time frame: Week 4, 8, 12, 16, 24, 36, 52
Change from baseline in ASDAS-CRP
Change in ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score Index) score in comparison with screening (from 0 to \> 3.5). The maximum change is considered to be better outcome
Time frame: Week 4, 8, 12, 16, 24, 36, 52
Change from baseline in SF-36
Change in SF-36 (The Short Form-36) score in comparison with screening (physical component) (from 15.9 to 62.1). The maximum change is considered to be better outcome
Time frame: Week 16, 36, 52
Frequency of AE/SAE
Percentage of patients with AE (adverse events) /SAE (serious adverse events)
Time frame: Week 60
Plan to share: No
Ran from Feb 2018 to primary completion in Dec 2018, 10 months.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 10 months is below that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BCD-085